Dentsply Sirona Appoints Glenn Coleman as Chief Financial Officer

Dentsply Sirona today announced that Glenn Coleman has been appointed Executive Vice President and Chief Financial Officer, effective September 26, 2022. He succeeds Barbara Bodem, who has served as Interim Chief Financial Officer since May 2022. Ms. Bodem will remain with the company and continue to serve as an advisor to Mr. Coleman until October 24, 2022.

Mr. Coleman brings 30 years of financial management expertise to Dentsply Sirona. He joins the Company from Integra Lifesciences Holdings Corporation (“Integra”), where he most recently served as Executive Vice President and Chief Operating Officer and previously held the role of Chief Financial Officer. Prior to Integra, Mr. Coleman held numerous financial management positions at leading global businesses, including Curtiss-Wright Corporation and Alcatel-Lucent. 

Simon Campion, Chief Executive Officer of Dentsply Sirona, said, “We are pleased to have Glenn join us in the CFO role. He is a transformational leader with a strong history of driving value creation and sustainable growth. Over the course of his career, he has overseen financial and operational functions across several geographies and industries, including healthcare. Glenn, like me, is a high-integrity leader who shares our commitment to accountability, operational rigor, discipline, and execution. I have no doubts that he will be a great thought partner for me and the other members of the leadership team.  Glenn’s leadership will be instrumental as we move forward with the previously announced review of the Company’s business and operations including competitive positioning and portfolio, margin enhancement opportunities, and capital structure.”

Mr. Coleman said, “I’m excited to join Dentsply Sirona as the Company prepares to enter its next chapter. I look forward to working with Simon and rest of the team to bring greater focus and discipline to our execution, advance our financial, operational, and strategic goals, and ultimately deliver long-term growth and value creation.”

Mr. Campion continued, “On behalf of the Company, I would like to express our gratitude to Barbara for her service as Interim CFO. During her tenure, Barbara enhanced key financial processes, helped build improved management systems, and advanced our top operational priorities. We look forward to continuing to benefit from her exceptional skill and leadership during the transition.”

About Glenn Coleman

Mr. Coleman previously served as Executive Vice President & Chief Operating Officer at Integra Lifesciences Holdings Corporation; a role held since 2019. As Chief Operating Officer, Mr. Coleman led operations and most of Integra’s talent force, including clinical, R&D, manufacturing, and quality functions while also leading the international team. Mr. Coleman was previously Integra’s Chief Financial Officer overseeing the finance department, including accounting and financial reporting, budgeting, internal audit, tax, treasury, investor relations, and information technology while also leading the international business. Prior to Integra, Mr. Coleman spent 25 years in financial management positions with leading global businesses, including Curtiss-Wright Corporation and Alcatel-Lucent, and began his career at PricewaterhouseCoopers LLP.

Mr. Coleman earned a Bachelor of Science from Montclair State University and has been a CPA in New Jersey for more than 25 years.         

DISCLAIMER

This information and any attachment thereto contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance. These forward-looking statements reflect views and assumptions regarding expectations and projections about future events and are based on currently available information or information available on the date of any document incorporated by reference. You can generally identify these forward-looking statements by the use of words such as "may," "could," "estimate," "will," "believe," "anticipate," "think," "intend," "expect," "project," "plan," "target," "forecast", and similar words and expressions. However, these words are not the exclusive means of identifying such statements. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and may include statements relating to future revenues, expenses, margins, profitability, net income/(loss), earnings per share and other measures of results of operations and the prospects of future growth of our business. These forward-looking statements are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. For a discussion of such risks, uncertainties and other matters that could cause actual results to differ materially, including risks relating to, among other factors, the market for dental products and services, pricing, future sales volume of the Company’s products, the possibility of changing economic, market and competitive conditions, dependence on products, dependence on key personnel, technological developments, intense competition, market uncertainties, dependence on distributors, ability to manage growth, dependence on key suppliers, dependence on key members of management, government regulation, our ability to integrate the businesses of Dentsply Sirona, acquisitions and affiliations, readers are urged to carefully review and consider various disclosures made by the Company and Dentsply Sirona in their public filings, including in their Annual Reports on Form 10-K and in their reports on Forms 10-Q and 8-K filed with the Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on such statements, which speak only as of the date hereof. Except as required by law, the Company does not assume any obligation to update any forward-looking statements contained in this document or the attachments to reflect new information or future events or developments after the date any such statement is made.

Über Dentsply Sirona

Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world class brands. Dentsply Sirona’s products provide innovative, high-quality and effective solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona’s headquarter is located in Charlotte, North Carolina. The company’s shares are listed in the United States on NASDAQ under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Firmenkontakt und Herausgeber der Meldung:

Dentsply Sirona
Sirona Straße 1
A5071 Wals bei Salzburg
Telefon: +43 (662) 2450-0
http://www.dentsplysirona.com

Ansprechpartner:
Niña Espiritu
Edelman
Telefon: +49 (69) 509546339
E-Mail: dentsplysirona@edelman.com
Marion Par-Weixlberger
Director of PR & Corporate Communications
Telefon: +43 (662) 2450-588
E-Mail: marion.par-weixlberger@dentsplysirona.com
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel